PRALUENT® (alirocumab) Phase 3 Patient Populations

PRALUENT phase 3 clinical trial program evaluating Q2W dosing enrolled over 3400 patients, including those with clinical ASCVD or HeFH1,2

Patient Populations within the PRALUENT Phase 3 placebo controlled clinical trial programs.

References:

  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.
  2. Data on file, Sanofi/Regeneron.
  3. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-2934.

Download Resources